Tarlatamab trials for Lung cancer

All Tarlatamab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Tarlatamab for Lung cancer

• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 164 locations
• A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
  NCT07037758 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 19 locations
• A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
  NCT07203053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
  NCT07778316 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 2 locations
• Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
  NCT06814496 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 2 locations
• Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
  NCT07016230 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
  NCT07531095 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 27 locations
• Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
  NCT07242547 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
  NCT07803848 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
  NCT06598306 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• Tarlatamab for SCLC Brain Metastases
  NCT07402343 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
  NCT07423585 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
  NCT06937905 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 40 locations

Common questions

How many trials study Tarlatamab for Lung cancer?

13 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.